Orbis Medicines, a Denmark-based company involved in oral macrocycle drug discovery, has announced the close of a €90m (US$94m) Series A funding round, bringing the total amount raised by the…
Denmark: Orbis Medicines closes Series A funding and names Graugaard as CEO
…
…






